Evaluating the short-term cost-effectiveness of liraglutide versus lixisenatide in patients with type 2 diabetes in the United States

2017 ◽  
Vol 20 (11) ◽  
pp. 1117-1120 ◽  
Author(s):  
B. Hunt ◽  
C.C. McConnachie ◽  
C. Gamble ◽  
T. Dang-Tan
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Short Term

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States

2007 ◽  
Vol 24 (2) ◽  
pp. 273-290 ◽  
Author(s):  
William J. Valentine ◽  
K. M. Erny-Albrecht ◽  
J. A. Ray ◽  
S. Roze ◽  
D. Cobden ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
Insulin Detemir ◽  
The United States ◽  
Oral Agents ◽  
Modeling Study

1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1158-P
Author(s):  
ODETTE REIFSNIDER ◽  
PRATIK PIMPLE ◽  
MATTHEW J.D. STARGARDTER ◽  
SARAH BRAND ◽  
NIHAR DESAI ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document